179 related articles for article (PubMed ID: 37988164)
1. Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration.
Liu A; Gammon ST; Pisaneschi F; Boda A; Ager CR; Piwnica-Worms D; Hong DS; Curran MA
JCI Insight; 2024 Jan; 9(1):. PubMed ID: 37988164
[TBL] [Abstract][Full Text] [Related]
2. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
[TBL] [Abstract][Full Text] [Related]
3. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
[TBL] [Abstract][Full Text] [Related]
4. Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.
Clavijo PE; Friedman J; Robbins Y; Moore EC; Smith E; Zauderer M; Evans EE; Allen CT
Cancer Immunol Res; 2019 Feb; 7(2):282-291. PubMed ID: 30514791
[TBL] [Abstract][Full Text] [Related]
5. Immunostimulatory RNA leads to functional reprogramming of myeloid-derived suppressor cells in pancreatic cancer.
Metzger P; Kirchleitner SV; Kluge M; Koenig LM; Hörth C; Rambuscheck CA; Böhmer D; Ahlfeld J; Kobold S; Friedel CC; Endres S; Schnurr M; Duewell P
J Immunother Cancer; 2019 Nov; 7(1):288. PubMed ID: 31694706
[TBL] [Abstract][Full Text] [Related]
6. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Jayaprakash P; Ai M; Liu A; Budhani P; Bartkowiak T; Sheng J; Ager C; Nicholas C; Jaiswal AR; Sun Y; Shah K; Balasubramanyam S; Li N; Wang G; Ning J; Zal A; Zal T; Curran MA
J Clin Invest; 2018 Nov; 128(11):5137-5149. PubMed ID: 30188869
[TBL] [Abstract][Full Text] [Related]
7. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
[TBL] [Abstract][Full Text] [Related]
8. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
9. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (C-C motif) ligand 26.
Chiu DK; Xu IM; Lai RK; Tse AP; Wei LL; Koh HY; Li LL; Lee D; Lo RC; Wong CM; Ng IO; Wong CC
Hepatology; 2016 Sep; 64(3):797-813. PubMed ID: 27228567
[TBL] [Abstract][Full Text] [Related]
11. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
12. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma.
Liu X; Tang R; Xu J; Tan Z; Liang C; Meng Q; Lei Y; Hua J; Zhang Y; Liu J; Zhang B; Wang W; Yu X; Shi S
Gut; 2023 Nov; 72(12):2329-2343. PubMed ID: 37541772
[TBL] [Abstract][Full Text] [Related]
13. Depleting Ly6G Positive Myeloid Cells Reduces Pancreatic Cancer-Induced Skeletal Muscle Atrophy.
Deyhle MR; Callaway CS; Neyroud D; D'Lugos AC; Judge SM; Judge AR
Cells; 2022 Jun; 11(12):. PubMed ID: 35741022
[TBL] [Abstract][Full Text] [Related]
14. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
15. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.
Keenan BP; Saenger Y; Kafrouni MI; Leubner A; Lauer P; Maitra A; Rucki AA; Gunderson AJ; Coussens LM; Brockstedt DG; Dubensky TW; Hassan R; Armstrong TD; Jaffee EM
Gastroenterology; 2014 Jun; 146(7):1784-94.e6. PubMed ID: 24607504
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.
Porembka MR; Mitchem JB; Belt BA; Hsieh CS; Lee HM; Herndon J; Gillanders WE; Linehan DC; Goedegebuure P
Cancer Immunol Immunother; 2012 Sep; 61(9):1373-85. PubMed ID: 22215137
[TBL] [Abstract][Full Text] [Related]
18. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways.
Guo X; Qiu W; Liu Q; Qian M; Wang S; Zhang Z; Gao X; Chen Z; Xue H; Li G
Oncogene; 2018 Aug; 37(31):4239-4259. PubMed ID: 29713056
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
